Established in 1980, EIPICO produced 309.6 million units in 2024, registered 13 new pharmaceutical products, and launched 10 new medications in the Egyptian market. It also completed 95% of the EIPICO 3 factory, which will produce biosimilars and their preparations, at an investment of nearly $110 million. In December 2024, Arab API, a newly established joint venture by EIPICO, ACDIMA, and the Suez Canal Economic Zone Company for Investment, signed a contract to establish a pharmaceutical industrial zone with investments of $120 million. The Arab Company for Drug Industries & Medical Appliances owned a 50% stake in EIPECO as of March 2025.